share_log

Cantor Fitzgerald Initiates Coverage On This 'Attractively Valued' MedTech Stock

Cantor Fitzgerald Initiates Coverage On This 'Attractively Valued' MedTech Stock

康托·菲茨杰拉德开始对这一具有吸引力的医疗技术股票进行报道
Benzinga Real-time News ·  2022/09/08 14:24
  • Cantor Fitzgerald initiated coverage on Asensus Surgical Inc (NYSE:ASXC) with an Overweight rating and a price target of $1.50.
  • ASXC is a RoboticAssisted Surgery (RAS) company that digitizes the interface between the surgeon and patient to enable performance-guidance surgery through machine vision, augmented intelligence, and deep learning capabilities.
  • The analyst believes that Asensus Surgical's RAS system, Senhance, should drive better and more consistent procedural outcomes.
  • The $1.50 price target is based on a 23.1x EV/CY23E revenue/growth multiple, representing a slight premium to high-growth MedTech peers at 19.4x and a discount to Intuitive Surgical Inc (NASDAQ:ISRG) at 76.9x.
  • The analyst holds a favorable view of the estimated $56-billion laparoscopic surgery market that may achieve an estimated 15% CAGR over 2019-30, with a current penetration of less than 15% of WW surgeries.
  • The analyst believes ASXC's visualization technology is differentiated from competitors and should serve to drive fast adoption.
  • Price Action: ASXC shares are up 2.77% at $0.54 on the last check Thursday.
  • 康托·菲茨杰拉德在以下日期开始覆盖阿斯普斯外科公司(纽约证券交易所代码：ASXC)，评级为增持，目标价为1.50美元。
  • ASXC是一家机器人辅助手术(RAS)公司，将外科医生和患者之间的界面数字化，通过机器视觉、增强智能和深度学习功能实现性能指导手术。
  • 这位分析师认为，Ascount Surgical的RAS系统SEnhance应该会推动更好和更一致的程序结果。
  • 1.5美元的目标价基于23.1倍的EV/CY23E收入/增长倍数，略高于高增长的MedTech同行的19.4倍，低于直觉外科公司股份有限公司(纳斯达克：ISRG)为76.9倍。
  • 这位分析师对估计价值560亿美元的腹腔镜手术市场持乐观态度，该市场可能在2019-30年间实现约15%的复合年增长率，目前在全球手术中的渗透率不到15%。
  • 这位分析师认为，ASXC的可视化技术有别于竞争对手，应该有助于推动快速采用。
  • 价格行动：ASXC股价周四最后一次上涨2.77%，至0.54美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发